Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence

Table 3

Subgroup analysis based on afatinib medication timing and data sources.

Group	No. of studies	HR (95%CI)	PA	Heterogeneity test
				PH	I^2 (%)
PFS	8	1.20 (0.95, 1.51)	0.124	0.508	0.0
Management of afatinib
First-line	7	1.23 (0.98, 1.56)	0.080	0.570	0.0
≥Second-line	1	0.60 (0.19, 1.87)	0.379	—	—
Calculated HR (95%CI)
Yes	5	1.06 (0.77, 1.44)	0.728	0.483	0.0
No	3	1.39 (0.99, 1.96)	0.057	0.486	0.0

Notes: P_A: value for the test of association; P_H: value for the test of heterogeneity.